A New Potential Approach to Inotropic Therapy in the Treatment of Heart Failure

Garg, Vinisha; Frishman, William H.

doi:10.1097/crd.0b013e31827ed0c9

Cited by 12 publications

(7 citation statements)

References 43 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to its potential to become a marker of HF, Ucn-2 is still undergoing tests on both models. A study on a group of eight healthy men confirmed the hemodynamic effect, as well as the ability to decrease MAP and vascular resistance and increase the left ventricular ejection fraction [85]. In a combined clinical and experimental study, Ucn-2 was able to decrease PAH, improve right ventricle function, and improve pulmonary circulation [86].…”

Section: (D) Urocortin-2mentioning

confidence: 81%

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

Nikitiuk,

Rydzewska-Rosołowska,

Kakareko

et al. 2024

IJMS

View full text Add to dashboard Cite

Overhydration (OH) is a prevalent medical problem that occurs in patients with kidney failure, but a specific marker has still not been found. Patients requiring kidney replacement therapy suffer from a water imbalance, which is correlated with mortality rates in this population. Currently, clinicians employ techniques such as bioimpedance spectroscopy (BIS) and ultrasound (USG) markers of overhydration or markers of heart and kidney function, namely NT-pro-BNP, GFR, or creatinine levels. New serum markers, including but not limited to Ca-125, galectin-3 (Gal-3), adrenomedullin (AMD), and urocortin-2 (UCN-2), are presently under research and have displayed promising results. Ca-125, which is a protein mainly used in ovarian cancer diagnoses, holds great potential to become an OH marker. It is currently being investigated by cardiologists as it corresponds to the volume status in heart failure (HF) and ventricular hypertrophy, which are also associated with OH. The need to ascertain a more precise marker of overhydration is urgent mainly because physical examinations are exceptionally inaccurate. The signs and symptoms of overhydration, such as edema or a gradual increase in body mass, are not always present, notably in patients with chronic kidney disease. Metabolic disruptions and cachexia can give a false picture of the hydration status. This review paper summarizes the existing knowledge on the assessment of a patient’s hydration status, focusing specifically on kidney diseases and the role of Ca-125.

show abstract

Section: (D) Urocortin-2mentioning

confidence: 81%

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

Nikitiuk,

Rydzewska-Rosołowska,

Kakareko

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…In general, the changes in Ucn III in Groups B and C could represent a local protective mechanism to stressful stimuli, although we could not draw conclusions on whether the expression changes in the ligands and receptors is a compensatory rather than a causative mechanism. Further studies in larger groups could clarify its involvement in fetal development and pathology, especially as urocortins have recently been identified as a new group of inotropic factors with multiple and important effects on the cardiovascular, hemodynamic, neurohormonal and renal system 51,52 and possibly novel players in the pathophysiology of the heart and its treatment.…”

Section: Discussionmentioning

confidence: 99%

Corticotropin-releasing factor (CRF) system localization in human fetal heart

Chouridou

Lambropoulou

Koureta

et al. 2016

View full text Add to dashboard Cite

oBJectIVe: the corticotropin-releasing factor (cRf) family consists of the neuropeptides cRf, ucn I, II and III and the binding sites cRfR1, cRfR2 and cRf-BP. It regulates stress response and the homeostasis of an organism. In this study, we examined the presence of the cRf system in the human hearts of normal and pathological fetuses. desIGn: Heart tissues from 40 archival human fetuses were divided into Group A (without pathology, 'normal'), Group B (with chromosomal abnormalities) and Group c (with congenital disorders). Immunohistochemistry was used to localize the cRf system. Results correlated to gestational trimester and pathology. ResuLts: Immunoreactivity for all antigens was found in cardiac myocytes of all groups, in almost all samples, except ucn III which was present in almost half of the fetuses of Groups B and c and was not detected at all in Group A. ucn III was more often present during the earlier stage of development (<21weeks) and in fetuses with congenital disorders. In a fetus diagnosed with heart pathology, all but ucn III antigens were also present. concLusIons: we localized a complete cRf system in the human fetal heart and correlated the presence of ucn III to development and pathology. More studies are needed to verify and clarify the exact role of the cRf system in the human fetal heart.

show abstract

“…Binding of these hormones to CRF-R2 receptors causes activation of several second messenger cascades leading to peripheral vasodilation, inotropic and chronotropic effects, anti-inflammatory effects, and anti-ischemic effects. 74,75 In patients with stable HF as well as with AHF, infusion of urocortin-2 has been shown to increase cardiac output (CO), decrease SVR, and decrease PCWP, although the latter observations were not statistically significant. 76,77 Similar hemodynamic findings have been observed following administration of human stresscopin to patients with stable HFrEF and low CO without significant effects on SBP.…”

Section: Investigational Drugs For Acute Hfmentioning

confidence: 99%

Emerging Therapies for Acute and Chronic Heart Failure

Hanigan

DiDomenico

2016

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Although the period from 1953 to 2001 resulted in the approval of more than 30 medications currently used to treat heart failure (HF), few novel drugs have been approved in the last decade. However, the investigational pipeline for HF medications once again appears promising. In patients with chronic heart failure with reduced ejection fraction (HFrEF), ivabradine and valsartan/sucubitril (LCZ696) were recently approved by the US Food and Drug Administration. Both agents have been shown to reduce the risk of cardiovascular death and HF hospitalization. In the treatment of acute HF, serelaxin and ularitide are the farthest along in development. Both agents have demonstrated favorable effects on surrogate end points and preliminary data suggest a possible mortality benefit with serelaxin. Consequently, phase 3 trials are ongoing to evaluate the effect of serelaxin and ularitide on clinical outcomes. Given the poor history of recent investigational acute HF drugs that have advanced to phase 3/4 studies, enthusiasm for both serelaxin and ularitide must be tempered until these trials are completed.

show abstract

A New Potential Approach to Inotropic Therapy in the Treatment of Heart Failure

Cited by 12 publications

References 43 publications

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients—A Systematic Review

Corticotropin-releasing factor (CRF) system localization in human fetal heart

Emerging Therapies for Acute and Chronic Heart Failure

Contact Info

Product

Resources

About